Cystic Fibrosis Foundation distributed the following clinical trial update on April 28, 2017. Click the trial title to get more details.
Phase 2a study of Galapagos GLPG2222 in adults with CF
Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of GLPG2222 in adults with CF who have two copies of the F508del mutation.
Age: 18 Years and Older
Mutation: Two Copies F508del
Fev1% Predicted: 40% or greater
Number of Visits: 5
Length of Participation: 10 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03119649